A share price of Allogene Therapeutics Inc [ALLO] is currently trading at $2.65, up 15.72%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ALLO shares have gain 12.29% over the last week, with a monthly amount drifted -6.36%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $11. On January 05, 2024, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. Citigroup initiated its recommendation with a Buy and recommended $7 as its price target on December 08, 2023.
Allogene Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $2.01 and $5.78. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $2.65 at the most recent close of the market. An investor can expect a potential return of 994.34% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
Trailing Twelve Months sales for Allogene Therapeutics Inc [NASDAQ:ALLO] were 0.09M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at -759.84% with Operating Profit Margin at -3148.66%, Pretax Profit Margin comes in at -3237.8%, and Net Profit Margin reading is -3237.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.54 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.40 points at the first support level, and at 2.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.78, and for the 2nd resistance point, it is at 2.90.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Allogene Therapeutics Inc [NASDAQ:ALLO] is 12.25. Further, the Quick Ratio stands at 12.25, while the Cash Ratio is 4.57. Considering the valuation of this stock, the price to sales ratio is 6157.13, the price to book ratio is 1.08.
Transactions by insiders
Recent insider trading involved MESSEMER DEBORAH M., Director, that happened on Jun 18 ’24 when 18641.0 shares were sold. Director, Humer Franz B completed a deal on May 30 ’24 to sell 11200.0 shares. Meanwhile, Director Belldegrun Arie bought 1.72 million shares on May 16 ’24.
